76 related articles for article (PubMed ID: 25069458)
1. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment.
Wenhui Z; Shuo L; Dabei T; Ying P; Zhipeng W; Lei Z; Xiaohui H; Jingshu G; Hongtao S; Qingyuan Z
Eur J Endocrinol; 2014 Oct; 171(4):527-33. PubMed ID: 25069458
[TBL] [Abstract][Full Text] [Related]
2. Hormone receptor mRNA and protein levels as predictors of premenopausal tamoxifen benefit.
Engström T; Ekholm M; Fernö M; Lundgren C; Nordenskjöld B; Stål O; Bendahl PO; Tutzauer J; Rydén L
Acta Oncol; 2024 Apr; 63():125-136. PubMed ID: 38587062
[TBL] [Abstract][Full Text] [Related]
3. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers.
Witkiewicz AK; Dasgupta A; Sotgia F; Mercier I; Pestell RG; Sabel M; Kleer CG; Brody JR; Lisanti MP
Am J Pathol; 2009 Jun; 174(6):2023-34. PubMed ID: 19411448
[TBL] [Abstract][Full Text] [Related]
4. Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century.
Yadav S; Karam D; Bin Riaz I; Xie H; Durani U; Duma N; Giridhar KV; Hieken TJ; Boughey JC; Mutter RW; Hawse JR; Jimenez RE; Couch FJ; Leon-Ferre RA; Ruddy KJ
Cancer; 2020 Jan; 126(1):26-36. PubMed ID: 31588557
[TBL] [Abstract][Full Text] [Related]
5. Androgen Receptor mRNA levels determine the prognosis in triple-negative breast cancer patients.
Govindan S; Siraganahalli Eswaraiah M; Basavaraj C; Adinarayan M; Sankaran S; Bakre M
BMC Cancer; 2020 Aug; 20(1):745. PubMed ID: 32778063
[TBL] [Abstract][Full Text] [Related]
6. Survival analysis in breast cancer using proteomic data from four independent datasets.
Ősz Á; Lánczky A; Győrffy B
Sci Rep; 2021 Aug; 11(1):16787. PubMed ID: 34408238
[TBL] [Abstract][Full Text] [Related]
7. Treatment and Prognosis of Male Breast Cancer: A Multicentric, Retrospective Study Over 11 Years in the Czech Republic.
Bielcikova Z; Holanek M; Selingerova I; Sorejs O; Kolarova I; Soumarova R; Proks J; Reifova L; Cmejlova V; Linkova L; Zabojnikova M; Chodacka M; Janovska L; Lisnerova L; Kasparova K; Pohankova D; Petruzelka L
Oncologist; 2024 Jun; 29(6):e750-e762. PubMed ID: 38431780
[TBL] [Abstract][Full Text] [Related]
8. A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression.
Feng Z; Wen H; Bi R; Ju X; Chen X; Yang W; Wu X
Sci Rep; 2016 May; 6():25408. PubMed ID: 27139372
[TBL] [Abstract][Full Text] [Related]
9. Role of androgen receptor expression in early stage ER+/PgR-/HER2- breast cancer.
Tagliaferri B; Quaquarini E; Palumbo R; Balletti E; Presti D; Malovini A; Agozzino M; Teragni CM; Terzoni A; Bernardo A; Villani L; Sottotetti F
Ther Adv Med Oncol; 2020; 12():1758835920958355. PubMed ID: 32994808
[TBL] [Abstract][Full Text] [Related]
10. Clinical, Pathological, and Prognostic Features of Male Breast Cancer: A Multicenter Study.
Accomasso F; Actis S; Minella C; Rosso R; Granaglia C; Ponzone R; Biglia N; Bounous VE
Curr Oncol; 2023 Nov; 30(11):9860-9871. PubMed ID: 37999136
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical and Molecular Characteristics of Anogenital Papillary Hidradenomas.
Karpathiou G; Sim A; Picot T; Mekhzoumi K; Chauleur C; Péoc'h M
Am J Dermatopathol; 2024 Feb; 46(2):79-82. PubMed ID: 38055985
[TBL] [Abstract][Full Text] [Related]
12. Expression and prognostic significance of lysozyme in male breast cancer.
Serra C; Vizoso F; Alonso L; Rodríguez JC; González LO; Fernández M; Lamelas ML; Sánchez LM; García-Muñiz JL; Baltasar A; Medrano J
Breast Cancer Res; 2002; 4(6):R16. PubMed ID: 12473177
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor and antiandrogen therapy in male breast cancer.
Di Lauro L; Barba M; Pizzuti L; Vici P; Sergi D; Di Benedetto A; Mottolese M; Speirs V; Santini D; De Maria R; Maugeri-Saccà M
Cancer Lett; 2015 Nov; 368(1):20-25. PubMed ID: 26276719
[TBL] [Abstract][Full Text] [Related]
14. A role for the androgen receptor in the treatment of male breast cancer.
Zhu J; Davis CT; Silberman S; Spector N; Zhang T
Crit Rev Oncol Hematol; 2016 Feb; 98():358-63. PubMed ID: 26669267
[TBL] [Abstract][Full Text] [Related]
15. Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling.
Narayanan R; Ahn S; Cheney MD; Yepuru M; Miller DD; Steiner MS; Dalton JT
PLoS One; 2014; 9(7):e103202. PubMed ID: 25072326
[TBL] [Abstract][Full Text] [Related]
16. Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis.
Zhang L; Fang C; Xu X; Li A; Cai Q; Long X
Biomed Res Int; 2015; 2015():357485. PubMed ID: 25695063
[TBL] [Abstract][Full Text] [Related]
17. AR collaborates with ERα in aromatase inhibitor-resistant breast cancer.
Rechoum Y; Rovito D; Iacopetta D; Barone I; Andò S; Weigel NL; O'Malley BW; Brown PH; Fuqua SA
Breast Cancer Res Treat; 2014 Oct; 147(3):473-85. PubMed ID: 25178514
[TBL] [Abstract][Full Text] [Related]
18. Long noncoding RNA
Li J; Ming Z; Yang L; Wang T; Liu G; Ma Q
Genes Dis; 2022 Nov; 9(6):1478-1492. PubMed ID: 36157489
[TBL] [Abstract][Full Text] [Related]
19. Bone Health Considerations in Breast Cancer.
Fessele KL
Semin Oncol Nurs; 2022 Apr; 38(2):151273. PubMed ID: 35477651
[TBL] [Abstract][Full Text] [Related]
20. A biomarker study in Peruvian males with breast cancer.
Castaneda CA; Castillo M; Bernabe LA; Sanchez J; Torres E; Suarez N; Tello K; Fuentes H; Dunstan J; De La Cruz M; Cotrina JM; Abugattas J; Guerra H; Gomez HL
World J Clin Oncol; 2021 Oct; 12(10):926-934. PubMed ID: 34733614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
